A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab

Gazit, 2005, The immunogenetics of pemphigus vulgaris, Autoimmun Rev, 4, 16, 10.1016/j.autrev.2004.05.002 Sticherling, 2012, Autoimmune blistering diseases of the skin, Autoimmun Rev, 11, 226, 10.1016/j.autrev.2011.05.017 Meyer, 2010, Geoepidemiologic considerations of auto-immune pemphigus, Autoimmun Rev, 9, A379, 10.1016/j.autrev.2009.10.009 Hertl, 2003, T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin, Autoimmun Rev, 2, 278, 10.1016/S1568-9972(03)00035-1 Sagi, 2008, Pemphigus and infectious agents, Autoimmun Rev, 8, 33, 10.1016/j.autrev.2008.07.021 Oostingh, 2002, Autoreactive T cell responses in pemphigus and pemphigoid, Autoimmun Rev, 1, 267, 10.1016/S1568-9972(02)00056-3 Bystryn, 2005, Pemphigus, Lancet, 336, 61, 10.1016/S0140-6736(05)66829-8 Chams-Davatchi, 2005, Pemphigus: analysis of 1209 cases, Int J Dermatol, 44, 470, 10.1111/j.1365-4632.2004.02501.x Martin, 2009, Interventions for pemphigus vulgaris and pemphigus foliaceus, Cochrane Database Syst Rev, CD006263 Martin, 2011, A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus, J Am Acad Dermatol, 64, 903, 10.1016/j.jaad.2010.04.039 Daniel, 2014, Management of pemphigus, F1000Prime Rep, 6, 32, 10.12703/P6-32 Meurer, 2012, Immunosuppressive therapy for autoimmune bullous diseases, Clin Dermatol, 30, 78, 10.1016/j.clindermatol.2011.03.013 Ahmed, 2007, Drug therapy of pemphigus vulgaris, G Ital Dermatol Venereol, l42, 391 Kasperkiewicz, 2012, Current therapy of the pemphigus group, Clin Dermatol, 30, 84, 10.1016/j.clindermatol.2011.03.014 Nigam, 2012, Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?, J Drugs Dermatol, 11, 622 Yeh, 2005, Treatment of pemphigus vulgaris: current and emerging options, Am J Clin Dermatol, 6, 327, 10.2165/00128071-200506050-00006 Perosa, 2005, CD20: a target antigen for immunotherapy of autoimmune diseases, Autoimmun Rev, 4, 526, 10.1016/j.autrev.2005.04.004 Dörner, 2009, Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis, Autoimmun Rev, 9, 82, 10.1016/j.autrev.2009.08.007 Guzman Moreno, 2009, B-cell depletion in autoimmune diseases. Advances in autoimmunity, Autoimmun Rev, 8, 585, 10.1016/j.autrev.2009.02.003 Grillo-López, 1999, Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma, Semin Oncol, 26, 66 Smolen, 2007, Consensus statement on the use of rituximab in patients with rheumatoid arthritis, Ann Rheum Dis, 66, 143, 10.1136/ard.2006.061002 Feldman, 2011, Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses, Expert Rev Clin Immunol, 7, 529, 10.1586/eci.11.22 Murrell, 2008, Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus, J Am Acad Dermatol, 58, 1043, 10.1016/j.jaad.2008.01.012 Kershenovich, 2014, Diagnosis and classification of pemphigus and bullous pemphigoid, Autoimmun Rev, 13, 477, 10.1016/j.autrev.2014.01.011 Baum, 2014, Diagnosis and classification of autoimmune blistering diseases, Autoimmun Rev, 13, 482, 10.1016/j.autrev.2014.01.047 Schmidt, 2010, Modern diagnosis of autoimmune blistering skin diseases, Autoimmun Rev, 10, 84, 10.1016/j.autrev.2010.08.007 Joly, 2007, A single cycle of rituximab for the treatment of severe pemphigus, N Engl J Med, 357, 545, 10.1056/NEJMoa067752 Cianchini, 2007, Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature, Arch Dermatol, 143, 1033, 10.1001/archderm.143.8.1033 Antonucci, 2007, Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases, J Dermatolog Treat, 18, 178, 10.1080/09546630701286110 Nagel, 2009, Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris, J Invest Dermatol, 129, 2202, 10.1038/jid.2009.27 Eming, 2008, Rituximab exerts a dual effect in pemphigus vulgaris, J Invest Dermatol, 128, 2850, 10.1038/jid.2008.172 Schmidt, 2009, Immunogenicity of rituximab in patients with severe pemphigus, Clin Immunol, 132, 334, 10.1016/j.clim.2009.05.007 Goh, 2007, Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients, Br J Dermatol, 156, 990, 10.1111/j.1365-2133.2007.07800.x Müller, 2010, Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris, Dermatol Res Pract, 2010, 321950, 10.1155/2010/321950 Reguiai, 2012, Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up, J Am Acad Dermatol, 67, 623, 10.1016/j.jaad.2011.12.019 Kim, 2011, Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients, Dermatology, 223, 182, 10.1159/000332848 Gregoriou, 2014, Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial, Dermatology, 228, 158, 10.1159/000357031 Lunardon, 2012, Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients, Arch Dermatol, 148, 1031, 10.1001/archdermatol.2012.1522 Pfütze, 2009, Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab, Dermatology, 218, 237, 10.1159/000187431 Balighi, 2013, Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial, Int J Dermatol, 52, 862, 10.1111/j.1365-4632.2012.5847.x Colliou, 2013, Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response, Sci Transl Med, 5, 175ra30, 10.1126/scitranslmed.3005166 Salopek, 2002, Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder, J Am Acad Dermatol, 47, 785, 10.1067/mjd.2002.126273 Cooper, 2003, Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab), Clin Exp Dermatol, 28, 366, 10.1046/j.1365-2230.2003.01283.x Virgolini, 2003, Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case, Haematologica, 88, ELT24 Herrmann, 2003, Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab), Br J Dermatol, 148, 602, 10.1046/j.1365-2133.2003.05209_10.x España, 2004, Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations, J Am Acad Dermatol, 50, 974, 10.1016/j.jaad.2003.08.021 Morrison, 2004, Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab), J Am Acad Dermatol, 51, 817, 10.1016/j.jaad.2004.06.007 Dupuy, 2004, Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody), Arch Dermatol, 140, 91, 10.1001/archderm.140.1.91 Wenzel, 2005, Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants, Acta Derm Venereol, 85, 185 Arin, 2005, Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus, Br J Dermatol, 153, 620, 10.1111/j.1365-2133.2005.06651.x Cecchi, 2005, Severe pemphigus vulgaris treated with rituximab (Mabthera), J Dermatol, 32, 862, 10.1111/j.1346-8138.2005.tb00862.x Niedermeier, 2006, Delayed response of oral pemphigus vulgaris to rituximab treatment, Eur J Dermatol, 16, 266 Rios-Fernández, 2007, Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases, Br J Dermatol, 157, 1271, 10.1111/j.1365-2133.2007.08189.x Esposito, 2006, Long-lasting remission of pemphigus vulgaris treated with rituximab, Acta Derm Venereol, 86, 87, 10.2340/00015555-0007 Marzano, 2008, Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab), Expert Rev Clin Immunol, 4, 351 Weger, 2008, Treatment failure with rituximab in a patient with pemphigus vulgaris, J Eur Acad Dermatol Venereol, 22, 387, 10.1111/j.1468-3083.2007.02340.x Wollina, 2008, Rituximab therapy of recalcitrant bullous dermatoses, J Dermatol Case Rep, 2, 4, 10.3315/jdcr.2008.1007 Sorce, 2008, Rituximab in refractory pemphigus vulgaris, Dermatol Ther, 21, S6, 10.1111/j.1529-8019.2008.00194.x Tournadre, 2008, Polymyositis and pemphigus vulgaris in a patient: successful treatment with rituximab, Joint Bone Spine, 75, 728, 10.1016/j.jbspin.2007.10.010 Menezes, 2010, Pemphigus vulgaris—still a difficult disease to treat, Int J Dermatol, 49, 230, 10.1111/j.1365-4632.2009.04192.x Schmidt, 2005, Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab, Br J Dermatol, 153, 449, 10.1111/j.1365-2133.2005.06740.x Bomm, 2013, Off-label use of rituximab in dermatology: pemphigus treatment, An Bras Dermatol, 88, 676, 10.1590/abd1806-4841.20131905 Kim, 2013, Successful single-cycle rituximab treatment in a patient with pemphigus vulgaris and squamous cell carcinoma of the tongue and IgG antibodies to desmocollins, J Am Acad Dermatol, 69, e26, 10.1016/j.jaad.2012.12.967 Corral, 2013, Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab, An Bras Dermatol, 88, 639, 10.1590/abd1806-4841.20131990 Fuertes, 2010, Rituximab in childhood pemphigus vulgaris: a long-term follow-up case and review of the literature, Dermatology, 221, 13, 10.1159/000287254 Schmidt, 2007, Rituximab in autoimmune bullous diseases: mixed responses and adverse effects, Br J Dermatol, 156, 352, 10.1111/j.1365-2133.2006.07646.x Gregoriou, 2014, Pemphigus vulgaris of the epiglottis successfully treated with rituximab, J Eur Acad Dermatol Venereol, 10.1111/jdv.12536 Kasperkiewicz, 2010, Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients, J Am Acad Dermatol, 65, 552, 10.1016/j.jaad.2010.07.032 Horváth, 2012, Low-dose rituximab is effective in pemphigus, Br J Dermatol, 166, 405, 10.1111/j.1365-2133.2011.10663.x Kanwar, 2013, Efficacy and safety of rituximab treatment in Indian pemphigus patients, J Eur Acad Dermatol Venereol, 27, e17, 10.1111/j.1468-3083.2011.04391.x Matsukura, 2012, Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients, Arch Dermatol, 148, 734, 10.1001/archdermatol.2011.3320 Cianchini, 2012, Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up, J Am Acad Dermatol, 67, 617, 10.1016/j.jaad.2011.11.007 Kasperkiewicz, 2012, Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients, Br J Dermatol, 166, 154, 10.1111/j.1365-2133.2011.10585.x Behzad, 2012, Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris, Br J Dermatol, 166, 844, 10.1111/j.1365-2133.2011.10732.x Kanwar, 2014, Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study, Br J Dermatol, 170, 1341, 10.1111/bjd.12972 Heelan, 2014, Durable remission of pemphigus with a fixed-dose rituximab protocol, JAMA Dermatol, 150, 703, 10.1001/jamadermatol.2013.6739 Cho, 2013, Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities, J Eur Acad Dermatol Venereol., 28, 186, 10.1111/jdv.12080 Kim, 2011, Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients, Br J Dermatol, 165, 646, 10.1111/j.1365-2133.2011.10411.x Cho, 2014, First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus, Acta Derm Venereol, 94, 472, 10.2340/00015555-1746 Craythorne, 2011, Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris, J Am Acad Dermatol, 65, 1064, 10.1016/j.jaad.2010.06.033 Shimanovich, 2008, Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins, Br J Dermatol, 158, 382, 10.1111/j.1365-2133.2007.08358.x Belgi, 2006, Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed, Clin Exp Dermatol, 31, 143, 10.1111/j.1365-2230.2005.01941.x Barrera, 2007, Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris, J Dermatolog Treat, 18, 312, 10.1080/09546630701323988 Faurschou, 2008, Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris, Int J Dermatol, 47, 292, 10.1111/j.1365-4632.2008.03423.x Craythorne, 2011, Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations, J Oral Pathol Med, 40, 616, 10.1111/j.1600-0714.2011.01017.x Kong, 2005, Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab), Pediatr Dermatol, 2, 461, 10.1111/j.1525-1470.2005.00118.x Kanwar, 2012, Childhood pemphigus vulgaris successfully treated with rituximab, Indian J Dermatol Venereol Leprol, 78, 632, 10.4103/0378-6323.100587 Diamanti, 2007, B cells in SLE: different biological drugs for different pathogenic mechanisms, Autoimmun Rev, 7, 143, 10.1016/j.autrev.2007.02.010 Kamal, 2014, The efficacy of novel B cell biologics as the future of SLE treatment: A review, Autoimmun Rev., 13, 1094, 10.1016/j.autrev.2014.08.020 Doria, 2012, Controversies in rheumatism and autoimmunity, Autoimmun Rev, 11, 555, 10.1016/j.autrev.2011.10.023 van Vollenhoven, 2012, Rituximab—shadow, illusion or light?, Autoimmun Rev, 11, 563, 10.1016/j.autrev.2011.10.013 Isenberg, 2012, Rituximab—it was the best of times, it was the worst of times, Autoimmun Rev, 11, 790, 10.1016/j.autrev.2012.02.005 Kattah, 2013, Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases, Autoimmun Rev, 12, 854, 10.1016/j.autrev.2012.09.002 Atzeni, 2013, Different effects of biological drugs in rheumatoid arthritis, Autoimmun Rev, 12, 575, 10.1016/j.autrev.2012.10.020 Caporali, 2009, Long term treatment of rheumatoid arthritis with rituximab, Autoimmun Rev, 8, 591, 10.1016/j.autrev.2009.02.008 Ferri, 2011, Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature, Autoimmun Rev, 11, 48, 10.1016/j.autrev.2011.07.005 Berman, 2013, Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab, Autoimmun Rev, 12, 1085, 10.1016/j.autrev.2013.05.004 Khattri, 2012, B-cell directed therapies in antiphospholipid antibody syndrome—new directions based on murine and human data, Autoimmun Rev, 11, 717, 10.1016/j.autrev.2011.12.011 Cornec, 2009, Critical analysis of rituximab-induced serological changes in connective tissue diseases, Autoimmun Rev, 8, 515, 10.1016/j.autrev.2009.01.007 Levy, 2014, Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature, Autoimmun Rev, 13, 1055, 10.1016/j.autrev.2014.08.036 Shetty, 2013, Preliminary analysis of mortality associated with rituximab use in autoimmune diseases, Autoimmunity, 46, 487, 10.3109/08916934.2013.838563 Ahmed, 2006, Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin, N Engl J Med, 355, 1772, 10.1056/NEJMoa062930 Leuci, 2009, Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells, G Ital Dermatol Venereol, 144, 379 Mohrbacher, 2005, B cell non-Hodgkin's lymphoma: rituximab safety experience, Arthritis Res Ther, 7, S19, 10.1186/ar1739